Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
Provided by
Dow Jones
14:01 EST--Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Shares of Bristol Myers Squibb fell after the U.S. Food and Drug Administration delayed approval for Abecma, a blood cancer treatment it developed with 2seventy Bio, to be used earlier in the treatment process. It is currently approved for use after four or more prior lines of therapy. Bristol Myers and 2seventy share all profit and losses for the drug. Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
November 20, 2023 14:16 ET (19:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing